Gempharmatech Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 23.95%

Gempharmatech Co. Ltd. A (688046) has an Asset Resilience Ratio of 23.95% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gempharmatech Co. Ltd. A (688046) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥670.25 Million

≈ $98.08 Million USD Cash + Short-term Investments

Total Assets

CN¥2.80 Billion

≈ $409.51 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Gempharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. See net assets of Gempharmatech Co. Ltd. A for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Gempharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688046 stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥670.25 Million	23.95%
Total Liquid Assets	CN¥670.25 Million	23.95%

Asset Resilience Insights

Good Liquidity Position: Gempharmatech Co. Ltd. A maintains a healthy 23.95% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Gempharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Gempharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	30.29%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Shanghai Junshi Biosciences Co Ltd SHG:688180	Biotechnology	4.28%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	83.49%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	41.74%

Annual Asset Resilience Ratio for Gempharmatech Co. Ltd. A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Gempharmatech Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	18.17%	CN¥467.34 Million ≈ $68.39 Million	CN¥2.57 Billion ≈ $376.46 Million	-6.58pp
2023-12-31	24.74%	CN¥637.72 Million ≈ $93.32 Million	CN¥2.58 Billion ≈ $377.18 Million	-10.37pp
2022-12-31	35.11%	CN¥791.24 Million ≈ $115.78 Million	CN¥2.25 Billion ≈ $329.79 Million	+15.59pp
2021-12-31	19.52%	CN¥205.80 Million ≈ $30.11 Million	CN¥1.05 Billion ≈ $154.29 Million	+12.58pp
2019-12-31	6.93%	CN¥26.92 Million ≈ $3.94 Million	CN¥388.14 Million ≈ $56.80 Million	--

pp = percentage points

About Gempharmatech Co. Ltd. A

SHG:688046 China Biotechnology

Market Cap

$1.22 Billion

CN¥8.35 Billion CNY

Market Cap Rank

#8310 Global

#2137 in China

Share Price

CN¥20.36

Change (1 day)

-1.17%

52-Week Range

CN¥11.60 - CN¥20.66

All Time High

CN¥34.14